Patent ID: 7892751
Filing Date: 2011-02-22
Classification: G01N

Abstract:
1. A method of screening for evidence of a neurodegenerative disease or condition in a subject, the method comprising the steps of: obtaining a sample of cerebral spinal fluid from the subject, oxidizing the sample with an oxidizing agent or electromotive force to unmask any antiphospholipid autoantibody therein; assaying the oxidized sample for the presence of at least one oxidized antiphospholipid autoantibody; and determining if there is a decrease in a level of at least one antiphospholipid autoantibody in the oxidized sample over a baseline value, wherein the baseline value is an average value of the level of the at least one oxidized antiphospholipid autoantibody in a population of control individuals, and correlating a decrease with evidence of a neurodegenerative disease or condition in said subject.